Can Ozempic Make India’s Workforce Healthier And Wealthier?

GLP-1 drugs like Ozempic began their journey as a treatment for one thing: Type 2 diabetes. Then came the weight-loss boom, turning a niche diabetes injection into a global cultural phenomenon. Now, the story is expanding again, this time with an even bigger promise. Better health, the claim goes, should mean fewer sick days, more focus at work, and people staying economically productive for longer.

It’s a compelling pitch. It’s also increasingly being used to justify billions of dollars in spending on these drugs. But until recently, nobody had actually tested whether it was true. A group of economists finally did, using years of Danish administrative data, and the answer they found was not what most people expected.

This matters enormously for India right now, because India is effectively running its own uncontrolled version of this experiment. Semaglutide’s patent lapsed here in March 2026, prices have crashed, and millions of people are newly within reach of a drug that was, until recently, a luxury import. The only thing missing is the data to tell us what any of this is actually doing to people’s health, jobs, and incomes.
1. Why You Can’t Just Compare Users to Non-Users
2. What the Danish Study Actually Found
3. Where the Financial Gain Really Went
4. India’s Diabetes and Pre-Diabetes Problem, By the Numbers
5. What Changes When You Bring This Drug to India

1. Why You Can’t Just Compare Users to Non-Users

Before getting to the results, it’s worth understanding why this is a genuinely hard question to answer. If you simply compare people who take Ozempic against people who don’t, and find that the drug users do better at work, you haven’t really learned anything useful. People who walk into a clinic, get a prescription, and commit to an injectable medication for years are not a random slice of the population. They may be sicker in specific ways, but they might also be more informed, more motivated, or more connected to the healthcare system in the first place. Any of those traits could independently affect someone’s job and income, completely apart from whether the drug itself works.

So a team of five economists, working with Danish administrative records, designed something smarter. Instead of comparing users to non-users, they compared people who started taking Ozempic within the drug’s first seventeen months on the Danish market to people who started the exact same drug roughly four years later. They then matched the two groups closely on age, sex, diabetes status, obesity, and a long list of social and economic characteristics. The result was 7,011 early starters, each paired with a near-identical later starter, together covering over 71% of everyone eligible in the early group.

The logic here is simple but powerful. Both groups eventually took the drug, so they’re far more alike than users and non-users would ever be. The only real difference between them is timing. That makes the later group a reasonable stand-in for what might have happened to the early group if their treatment had simply started four years later.

One important caveat shapes everything that follows: everyone in this sample was between 30 and 59 years old, and 84% of them had diabetes. This was not a broad weight-loss population chasing a slimmer body, it was mostly middle-aged people managing a chronic disease, most of whom already had jobs.

2. What the Danish Study Actually Found

With that context in place, here’s what happened after people started the drug.

First, most people actually stuck with it. Four years in, 75% of early users had filled at least one semaglutide prescription that quarter, a remarkably high persistence rate for a long-term medication, helped along by Denmark’s heavy drug subsidies.

Then, sick leave started falling. Denmark’s main measure of long-term sick leave captures medically certified absences lasting more than 30 days. Before treatment, people in the study spent about 5.5% of their months on this kind of leave. After starting the drug, that number fell by 0.95 percentage points, a 17.3% drop. In other words, roughly one in every six long sickness absences simply stopped happening.

The effect also grew over time. In the first two years, sick leave fell by about 0.8 percentage points. By years three and four, that decline had widened to around 1.1 points, consistent with health improvements building gradually rather than happening overnight. Other health-related indicators moved the same way: fewer emergency room visits, fewer cardiovascular drug prescriptions, and fewer doctor consultations overall.

Here’s where the story takes an unexpected turn. The very same treatment that cut long-term sickness absence by a sixth produced no detectable improvement in whether people were employed, how many hours they worked, or what they earned. And this wasn’t simply noisy, inconclusive data — the estimates were precise enough to rule out any employment gain larger than 0.4 percentage points, or any income gain larger than 0.7%. The researchers split the results by sex, age, and education looking for the effect to show up somewhere. It didn’t. Some estimates were even slightly negative.

Health clearly improved. The economic markers barely moved at all.

3. Where the Financial Gain Really Went

The explanation isn’t medical, it’s institutional, and it might be the most useful idea in the entire paper.

In Denmark, employers generally cover an employee’s salary for the first 30 days of illness. After that, the local municipality steps in with sickness benefits, which for many lower-paid workers replace most of the income they’d otherwise lose. So a Danish worker who falls sick for two months takes only a modest financial hit, and if that illness is prevented entirely, their measured income doesn’t rise by much either, because it wasn’t falling by much in the first place.

The money is still being saved, it just lands somewhere else. The employer avoids paying those first 30 days. The municipality avoids paying afterward. The economic benefit shows up as a cost that quietly never appears on someone else’s books, not as a bigger paycheck for the worker.

It’s worth being precise about what this doesn’t mean. This is an offset, not a verdict. The study doesn’t run a full cost-benefit analysis weighing these savings against the price of the drug, and it says nothing about whether people become more productive while they’re actually sitting at their desks. “Ozempic pays for itself” is simply not a claim this research makes.

4. India’s Diabetes and Pre-Diabetes Problem, By the Numbers

Now bring this back to India, where the scale of the underlying problem is enormous.

Globally, around 12% of the population is expected to have diabetes. India’s diabetic population sits at roughly that same 12% mark. But the number that should really grab attention is pre-diabetes, an estimated 15% of India’s population currently falls into that category. Put together, more than one in four Indians either already has diabetes or is standing right at its edge.

This is compounded by another factor: India’s median age is significantly lower than that of most developed economies, which means these metabolic issues are showing up in people far earlier in life than they do elsewhere.

Meanwhile, access to treatment has changed dramatically and fast. Semaglutide’s core patent in India lapsed on March 20, 2026, and within weeks, more than 40 generic versions had entered the market. Prices that once sat between ₹8,800 and ₹11,000 a month for the branded drug dropped to somewhere between ₹1,300 and ₹4,200 for generics, in some cases even lower. In response, the original manufacturer cut its own prices too, by as much as 48% on some products.

5. What Changes When You Bring This Drug to India

Put the two ideas together, and a genuinely interesting opportunity emerges. If a quarter of India’s population is sitting in the diabetes-or-pre-diabetes zone, and the drug that helps manage this condition just became dramatically more affordable, this is one of the largest early-intervention opportunities in the world. Catching people at the pre-diabetic stage, before complications set in, is, medically speaking, the most valuable point to intervene. The mechanism of the drug doesn’t change based on how far along someone is; it works the same way whether the diagnosis is prediabetes or full diabetes. The regulatory approval for that earlier stage simply hasn’t caught up yet, anywhere in the world.

But the more important shift may be financial, not medical, and this is where India looks structurally different from Denmark.

In Denmark, when an employee falls sick for a long stretch, the employer covers the first month’s pay, and the government picks up the rest through sickness benefits. The worker is financially cushioned either way, which is exactly why preventing that illness didn’t show up as more income in their pocket, the savings went to the employer and the state instead.

In India, that cushion largely doesn’t exist. If a worker falls sick or loses their job, in most cases, they absorb that cost directly, with no employer-funded month and no government benefit stepping in behind it. Which means if this drug reduces long-term sickness for Indian workers the way it did in Denmark, the savings would very likely land somewhere different — directly with the worker, in the form of income and job security they would otherwise have lost.

What’s In It For You

If you’re a working professional in India, especially one juggling long hours, sedentary work, and a diet skewed toward convenience, this isn’t just a story about a trending weight-loss drug. It’s a preview of a genuine shift in how metabolic health and financial stability might connect for millions of Indians. Cheaper access to a drug like this could mean fewer sick days, more stable income, and a real shot at catching a preventable disease before it becomes a chronic one. But it also means understanding that this is still an emerging, evolving picture, not a guaranteed outcome, and that any decision to use these drugs belongs in a conversation with a qualified doctor, not a trend to follow on your own.

Disclamer- This content is for informational and educational purposes only and does not constitute investment, legal, or tax advice. Please consult qualified professionals before making any financial decisions. MintWit Financial Services LLP is an AMFI-registered Mutual Fund Distributor (ARN-283168); however, all investments are subject to market risks and returns are not assured.